Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

Vorasidenib

VORTEX (Alliance A072301)

Servier · Phase 3 · Recruiting · Enrollment 408

NCT07215910

Catalyst Primary completion. 05.31.2033. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy
RT then TMZ + vorasidenibnewly diagnosed grade 3 IDH-mutant astrocytoma40 mgITTplacebon/r

No efficacy figure is in this file for this study.